But 30-plus years ago, “it was free rein,” says Carasik, who has also designed scenes for inventors in movies like Batman Returns and Ghostbusters II. “So we went ahead and put them on the set.” A quick perusal of C&EN’s copy of the 1946 collection featured in the movie does reveal some interesting topics—including an eyewitness account of an atomic bomb explosion in the Pacific and a report on the stability of penicillin.
by Andrea Widener | January 21, 2023
They are there to work and need to be free from distractions. Help when asked. The most sure path to success is to give people the support they need. Explain what needs to be done and why and help them figure out how it can be accomplished. Then give them the tools they need to do it. Rearranging physical spaces to simplify access, providing scheduling flexibility, and breaking up tasks or information into smaller units are all possible accommodations that can be helpful for everyone.
by Brought to you by ACS Career Navigator | January 13, 2023
For $85 million, Moderna will purchase Japan-based OriCiro Genomics, which specializes in cell-free DNA synthesis and amplification technology. BioNTech will buy the London-headquartered company InstaDeep for $439 million and potentially up to $243 million in milestone payments. The transaction will allow BioNTech to leverage InstaDeep’s artificial intelligence and machine learning platforms for the discovery and development of immunotherapies and vaccines. /business/mergers-&-acquisitions/mRNA-giants-make-acquisitions/101/i2 20230112 Concentrates 101 2 /magazine/101/10102.html mRNA giants make acquisitions mergersAcquisitions, Moderna, BioNTech, InstaDeep, OriCiro con bus Shi En Kim business mergers-&-acquisitions biological-chemistry rna pharmaceuticals pharmaceutical-chemicals mRNA giants make acquisitions Chemical & Engineering News mRNA giants make acquisitions mRNA giants make acquisitions
by Shi En Kim | January 12, 2023
It is impossible to prove that a large manufacturing facility is completely free of ubiquitous, natural bacteria. These regulatory agencies have no real accountability to the public. Their heads are political appointees, often with no real subject matter expertise. The lower-level members are civil servants with the job security that guarantees.
January 12, 2023
Knowles Sponsor: Pfizer Endowment Fund Citation: For establishing proton-coupled electron transfer as a general approach to solve synthetic challenges in the areas of free radical chemistry, asymmetric catalysis, and organometallic chemistry Current position: Professor of chemistry, Princeton University Education: BS, chemistry, College of William and Mary; PhD, organic chemistry, California Institute of Technology Knowles on the most rewarding part of his job: “The process of taking an idea that begins as a drawing on a blackboard and developing it into something real that other people can actually use and build upon.”
by Nina Notman, special to C&EN | December 30, 2022
“There were difficult techniques, glove boxes, and everything had to be done in an oxygen-free environment. It was very interesting,” she says. She honed her understanding of organometallic chemistry doing her PhD work at the University of Aveiro, where, in 2003, she immersed herself in the then-obscure field of converting xylans into furfural. 2007 The big decision In September 2007, Sousa Dias began a postdoctoral fellowship at Nova and thought she was headed toward an academic career.
by Alex Scott | December 30, 2022
—EnginZyme raises $22 million for biomanufacturing “” The cell-free biomanufacturing start-up EnginZyme has raised $22 million in series B financing from Bunge Ventures, Sofinnova Partners, and others. The Swedish company aims to replace petrochemical production of plastics, rubber, and other materials with a process that uses enzymes and packed-bed reactors.
by Matt Blois | December 29, 2022